Avner Hagai - BrainsWay Founder and President and Director

BRSYF Stock  USD 3.15  0.00  0.00%   

President

Mr. Avner Hagai serves as CoChairman of the Board at Brainsway Ltd since November 7, 2006. Previously, he served as Chief Executive Officer at A.A. Glass Ltd. He also serves as Director at A. Haomer Ltd, A.H. Modiin Ltd, Siv Real Estate Ltd and Hofit Kibbutz Kinneret Ltd. since 2006.
Age 67
Tenure 18 years
Phone972 2 582 4030
Webhttps://www.brainsway.com

BrainsWay Management Efficiency

The company has return on total asset (ROA) of (0.0751) % which means that it has lost $0.0751 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2021) %, meaning that it generated substantial loss on money invested by shareholders. BrainsWay's management efficiency ratios could be used to measure how well BrainsWay manages its routine affairs as well as how well it operates its assets and liabilities.
BrainsWay has accumulated 754 K in total debt with debt to equity ratio (D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. BrainsWay has a current ratio of 7.56, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist BrainsWay until it has trouble settling it off, either with new capital or with free cash flow. So, BrainsWay's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BrainsWay sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BrainsWay to invest in growth at high rates of return. When we think about BrainsWay's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 12 records

PRESIDENT Age

Hemanth CFAVenus Concept
48
Gregg SuttonSurModics
64
Moshe CitronowiczApyx Medical
71
Michael KaravitisCutera Inc
54
Carlton RecklingSi Bone
62
Todd HornsbyApyx Medical
47
Jonathan HarrisOwlet Inc
59
Brent HauserCutera Inc
47
Scott YerbySi Bone
56
Brian GiambattistaVarex Imaging Corp
65
Mark JonaitisVarex Imaging Corp
62
Kimberley HoneysettVarex Imaging Corp
54
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel. Brainsway operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 118 people. BrainsWay [BRSYF] is a Pink Sheet which is traded between brokers over the counter.

Management Performance

BrainsWay Leadership Team

Elected by the shareholders, the BrainsWay's board of directors comprises two types of representatives: BrainsWay inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BrainsWay. The board's role is to monitor BrainsWay's management team and ensure that shareholders' interests are well served. BrainsWay's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BrainsWay's outside directors are responsible for providing unbiased perspectives on the board's policies.
Menachem Esq, Gen VP
Christopher Jako, Pres CEO
Avner Hagai, Founder and President and Director
Christopher Boyer, VP Marketing
Hadar Levy, VP COO
Yiftach Roth, Founder, Chief Scientist and Director
Moria Ankri, VP RD
Aron Tendler, Chief Officer
Pr Zangen, Member CoFounder
Richard Areglado, VP CFO

BrainsWay Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is BrainsWay a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Additional Information and Resources on Investing in BrainsWay Pink Sheet

When determining whether BrainsWay offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BrainsWay's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Brainsway Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Brainsway Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BrainsWay. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
For more detail on how to invest in BrainsWay Pink Sheet please use our How to Invest in BrainsWay guide.
You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Please note, there is a significant difference between BrainsWay's value and its price as these two are different measures arrived at by different means. Investors typically determine if BrainsWay is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BrainsWay's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.